The Alliance for Regenerative Medicine's second quarter report on financing and deal-making showed that cell and gene therapy companies raised $2.6bn globally in the second quarter, which was down 38% year-over-year. As in the first quarter, however, venture capital and upfront fees from deals outperformed other fundraising categories.
ARM's report covers gene and gene-edited cell therapies, cell therapies and tissue engineering firms, which raised a combined $4.8bn in...






